Implications of Recent Data from CheckMate-142 in CRC

Video

Transcript:

Tanios Bekaii-Saab, MD: At a very high level, we’ve already known that microsatellite instability determines a likelihood of a response to PD-1 inhibitors. We have 2 approvals, pembrolizumab and nivolumab, in this stage. At ASCO GI, we’ve heard updates about nivolumab in MSI-high patients, which seems very consistent with what we’d expect for this group of patients. Those responses occur in 30% to 40% of the patients, and many of the responses can come later. Some of these responses occur beyond 24 weeks, so stable disease can essentially transform into a PR and the PR can transform into a CR.

The other component of the presentation included—it was a separate presentation, but it was part of the same study—nivolumab plus ipilimumab, trying to understand the added benefit of CTLA-4 inhibitors to PD-1 inhibitors. We know that strategy has been looked at in melanoma, has been looked at in gastric cancer, and has been looked at in a number of different cancers. It does seem in colorectal cancer, like with other cancers, to add few more responders historically, at least when compared to a PD-1 inhibitor alone. So, there may be some benefit in doing this, even when we use 2 different doses of nivolumab and 2 different doses of ipilimumab.

The question that remains is, is this going to change the outcome for those patients? In all frankness, in my own clinic, I have patients on the single-agent PD-1 inhibitors who respond tremendously, and they respond for not just a few months but for a few years, and they will never need another agent. The question is, who are those patients who may need the added benefit of CTLA-4 inhibition, and how do we best study this?

At this point in time, I don’t think that these data will change how we practice in clinic. In other words, a patient with an MSI-high tumor remains, at this point of time, a candidate for either pembrolizumab or nivolumab. We have 2 sets of great data with nivolumab presented at ASCO GI. I think the role of ipilimumab in colorectal cancer would need to be explored further and is not yet ready for prime time in clinic.

Transcript Edited for Clarity

Related Videos
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Ilyas Sahin, MD
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer